Aptamers Engineered Nanocarriers for Cancer Therapy

Dr. Prashant Kesharwani is an Assistant Professor of Pharmaceutics at Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, India. His work focuses on translational nanomedicine, polymeric biomaterials, targeted drug delivery, nanoengineered drug delivery systems, and translational pharmaceutical research. He has contributed extensively to the scientific literature and has served as an editor of scholarly books. Dr. Kesharwani has received research funding from national agencies and has been recognized with awards and fellowships for his contributions to the field. His research interests include nanomedicine, targeted and stimuli-responsive drug delivery, polymeric nanocarriers, and related pharmaceutical applications. He is actively involved in scientific research, academic mentoring, and scholarly publishing.

• 1. Cell-SELEX technology for aptamer selection2. Biological characteristics of aptamers3. Mechanisms of multi-drug resistance of cancer4. Relevance of aptamers as targeting ligands for anticancer therapies5. Aptamers as smart ligands for nano-carriers cancer targeting6. Aptamer-functionalized liposomes for targeted cancer therapy7. Aptamer-functionalized micelles for targeted cancer therapy8. Aptamer-functionalized nanoparticles for targeted cancer therapy9. Aptamer-functionalized PLGA nanoparticles for targeted cancer therapy10. Aptamer-functionalized silica nanoparticles for targeted cancer therapy11. Aptamer-functionalized gold nanoparticles for targeted cancer therapy12. Aptamer-functionalized dendrimers for targeted cancer therapy13. Aptamer-functionalized carbon nanotubes for targeted cancer therapy14. Aptamer-functionalized quantum dots for targeted cancer therapy15. Cancer immunotherapy via nucleic acid aptamers16. Aptamer-based imaging and diagnostics for cancer cells17. Microdevice-based aptamer sensors18. Aptamer-based microfluidics for circulating tumor cells19. Aptamer-based theranostic approaches for treatment of cancer20. Challenges of aptamers as targeting ligands for anticancer therapies21. Clinical use and future perspective of aptamers